Intratumoral Heterogeneity in PD-L1 Immunoreactivity is Associated with Variation in Non-Small Cell Lung Carcinoma Histotype.
Accurate assessment of PD-L1 levels in non-small cell lung carcinoma (NSCLC) samples is complicated by intratumoral heterogeneity. We aimed to (i) establish whether intratumoral PD-L1 variation is associated with differences in local histotype, (ii) identify histotypes associated with a tendency for higher or lower PD-L1 scores, and (iii) estimate the frequency of clinically significant discordance in PD-L1 levels between intratumoral histotype areas. We reviewed 166 NSCLC resection specimens clinically tested for PD-L1 using the 22C3 pharmDx assay. Multiple histotypes were present in 55% (68/123) of non-mucinous adenocarcinoma samples. Solid histotypes had significantly higher PD-L1 levels than other histotypes, both when grouping samples by predominant histotype and when histotype areas within a tumor were compared (p-values <0.02). Lepidic areas had significantly lower PD-L1 levels than other histotypes areas within the same tumor (p-values <0.02). Discordance between intratumoral histotype areas at a clinically relevant threshold (1% or 50% PD-L1 tumor proportion score) was present in 32% (22/68) of non-mucinous adenocarcinoma specimens with multiple histotype areas. The lepidic histotype was most frequently involved in discordance. Intratumoral heterogeneity in PD-L1 is associated with variation in histotype. Over-representation of solid areas may increase the PD-L1 score assigned to a tumor, whereas over-representing lepidic areas may decrease the PD-L1 score. Evaluation of how histotype representation impacts the predictive value of PD-L1 testing is warranted. This article is protected by copyright. All rights reserved.